Devendra Barlewar, a 47-year-old scientist, successfully received a rare third kidney transplant at Amrita Hospital, leaving ...

Lack of steady income can cause patients to face difficulties in bearing treatment costs that can reach up to RM40,000 a year ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

Devendra Barlewar, a scientist from the Union Ministry of Defence, successfully underwent his third kidney transplant.

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

The prevention of multiple long term conditions needs to be higher up the healthcare agenda and for this to happen we need to be more precise about what we mean when talking about it. As populations ...

Beacon Journal sports writer George M. Thomas details the obstacles on his way to receiving a kidney transplant.

AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...

In view of the escalating burden of non-communicable diseases in the country, the Union Health Ministry on Thursday launched ...

As global warming spreads pests, diseases and toxins, new programs are developing to help medical professionals look at their ...

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2024 financial results and provided a corporate update.